New injection combo takes aim at tough skin cancers

NCT ID NCT07228442

Recruiting now Disease control Sponsor: Philogen S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This phase 2 trial tests a combination of two immune-boosting drugs, L19IL2 and L19TNF, injected directly into skin tumors. It is for people with advanced cutaneous squamous cell carcinoma whose cancer has worsened despite or who cannot tolerate standard immunotherapy. Up to 92 participants will receive weekly injections for up to 4 weeks, with a possible second course if the tumor shrinks or stabilizes. The goal is to see if this approach can shrink tumors and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: L19IL2 and L19TNF (a combination of two immune-boosting proteins injected directly into tumors)
What this could lead to: If it works, this could offer a new treatment option for people with advanced skin cancer who have run out of standard therapies.
What could go wrong: This is an early phase 2 trial with only 92 participants, so results may not apply to everyone. The treatment is injected directly into tumors, which may not be possible for all patients, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Andreas Syngros Hospital Of Venereal And Dermatological Diseases
NOT_YET_RECRUITING

Athens, 16121, Greece
Azienda Ospedaliero-Universitaria Senese
RECRUITING

Siena, 53100, Italy
Charite Universitaetsmedizin Berlin KöR
RECRUITING

Berlin, 10117, Germany
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, 00168, Italy
Hospital Clinic De Barcelona
RECRUITING

Barcelona, 08036, Spain
Humanitas Mirasole S.p.A.
RECRUITING

Rozzano, 20089, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale
RECRUITING

Naples, 80131, Italy
The Ohio State University Wexner Medical Center Clinical Laboratories
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UC Irvine Health- Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868-3201, United States
Universitaetsklinikum Augsburg
RECRUITING

Augsburg, 86179, Germany
Universitaetsklinikum Essen AöR
RECRUITING

Essen, 45147, Germany
Universitaetsklinikum Halle (Saale) AöR
RECRUITING

Halle, 06120, Germany
Universitaetsklinikum Heidelberg AöR
RECRUITING

Heidelberg, 69120, Germany
Universitaetsklinikum Schleswig-Holstein AöR
RECRUITING

Kiel, 24105, Germany
Universitaetsklinikum Tübingen AöR
RECRUITING

Tübingen, 72076, Germany
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.